Atlas Trials

Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Clinical trial NCT04782765 · UNKNOWN

Trial details

NCT number
NCT04782765
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Disease-free Survival Rate
Start date
2021-03-20
Primary completion
2023-03-20
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.